If you often pop up anti-anxiety and sleeping pills, beware! A research from the University of Warwick has found that there are linked to an increased risk of death.
The study shows that several anxiolytic (anti-anxiety) drugs or hypnotic drugs (sleeping pills) are associated with doubling the risk of mortality.
Although these findings are based on routine data and need to be interpreted cautiously, the researchers recommended that a greater understanding of their impact is essential.
Scott Weich, professor of Psychiatry at the University of Warwick, explained: "The key message here is that we really do have to use these drugs more carefully. This builds on a growing body of evidence suggesting that their side effects are significant and dangerous. We have to do everything possible to minimise over reliance on anxiolytics and sleeping pills."
The study accounted for other factors such as age, smoking and alcohol use, other prescriptions and socioeconomic status.
The study, published in the journal BMJ, tracked 34,727 people for seven-and-a-half years on average from the time that they first received prescriptions for either an anxiolytic or hypnotic drug.
Benzodiazepines were the most commonly prescribed drug class, including diazepam and temazepam.
The study also examined the effects of two other groups of drugs; the so-called 'Z-drugs' and all other anxiolytic and hypnotic drugs.
Many patients received more than one drug over the course of the study, and five percent received prescriptions for drugs from all three groups.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
